PTO/SR/21 (01-03)

	U.S. Pater	Approved for use through 04/30/2003. OMB 0651-003 nt and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under in 12 di von Reduction Act of 1995	Application Number	on of information unless it displays a valid OMB control number
TRANSMITTAL	Filing Date	July 9, 2003
FORM	First Named Inventor	Torsten Hoffmann
(to be used for all correspondence after initial	filing) Art Unit	1626
	Examiner Name	
Total Number of Pages in This Submission	5 Attorney Docket Number	20693 US2
	ENCLOSURES (Check all that	t apply)
Fee Transmittal Form  Fee Attached  Amendment/Reply  After Final  Affidavits/declaration(s)  Extension of Time Request  Express Abandonment Request  Information Disclosure Statement  Certified Copy of Priority Document(s)  Response to Missing Parts/ Incomplete Application  Response to Missing Parts under 37 CFR 1.52 or 1.53	Drawing(s)  Licensing-related Papers  Petition  Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Addre Terminal Disclaimer  Request for Refund  CD, Number of CD(s)  Remarks	After Allowance Communication to Group  Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)  Proprietary Information  Status Letter  Other Enclosure(s) (please Identify below):
SIGNA	TURE OF APPLICANT, ATTORN	EY, OR AGENT
•	ERTIFICATE OF TRANSMISSION	
	ransmitted to the USPTO or deposited with the Ur	nited States Postal Service with sufficient postage as first class
I hereby certify that this correspondence is being to mail in an envelope addressed to: Commissioner Typed or printed  Kimberly J. Prior	$\overline{}$	October 3, 2003

process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



## PATENT APPLICATION

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

ì

Inventor(s): Hoffmann et al.

Group: 1626

Serial No. 10/616,276, filed July 9, 2003

Examiner: Shameem, Golam M.

For: NK-1 RECEPTOR ACTIVE AMINE OXIDE PRODRUGS

# **INFORMATION DISCLOSURE STATEMENT**

Nutley, New Jersey 07110 October 3, 2003

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.

None of the documents listed on Form PTO 1449 are being submitted with this IDS because each document has been made of record in the grandparent application, Serial No. 09/904,059, filed July 12, 2001, now 6,593,472.

Serial No. 10/616,276

Filed: July 9, 2003

Since the Information Disclosure Statement is submitted before the mailing of the first Office Action on the merits or within three months of the filing date for the above application, no fee is due.

Respectfully submitted,

Attorney for Applicant(s)

Kimberly J. Prior (Reg. No. 41,483)

340 Kingsland Street

Nutley, New Jersey 07110 Telephone: (973) 235-6208 Telefax: (973) 235-2363

134853



f

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Complete if Known		
Application Number	10/616,276	
Filing Date	July 9, 2003	
First Name Inventor	Torsten Hoffmann et al.	
Group Art Unit	1626	
Examiner Name	Shameem, Golam M.	
Attorney Docket Number	20693 US2	

Sheet of 2

U.S. PATENT DOCUMENTS

		U.S. Patent Doci	ument			D. CD.11	
Examiner Initials'	Cite No. <sup>1</sup>	Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document		Date of Publication of Cited document MM-DD-YYYY	
	A1	5,691,336		Dorn et al.		11/25/1997	
	A2	5,972,938		Rupniak et al.		10/26/1999	
	A3	6,297,375		Bos et al.		10/02/2001	
							•
					-		
		E	DEICN DA'	TENT DOCUMENTS			
	Ι	Foreign Patent Docu			Date	e of Publication of	Т°
Examiner Initials'	Cite No.'	Office <sup>3</sup> Number <sup>4</sup>	Kind Code <sup>5</sup>	Name of Patentee or Applicant of Cited Document		Cited Document  MM-DD-YYYY	
	B1	WO 95/16679		Merck & Co.	06/2	22/1995	
	B2	WO 95/18124		Merck, Sharpe & Dohme	07/0	06/1995	
	В3	WO 95/23798		Merck & Co.	09/0	08/1995	
	B4	EP 103 545		F.Hoffmann-La Roche	05/3	30/2001	
	B5	EP 035 115		F.Hoffmann-La Roche	09/	13/2000	
							-
	i .	1			1		

Examiner	Date Considered	
Signature		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*Unique citation designation number. \*See attached Kinds of U.S. Patent Documents. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if English language Translation or abstract is attached.

Substitute for form 1449A/PTO Complete if Known INFORMATION DISCLOSURE 10/616,276 Application Number STATEMENT BY APPLICANT Filing Date July 9, 2003 First Name Inventor Torsten Hoffmann et al. (Use several sheets if necessary) Group Art Unit 1626 Examiner Name Shameem, Golam M. 2 Of 2 Attorney Docket Number 20693 US2 Sheet

#### NON PATENT LITERATURE DOCUMENTS

	1	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials'	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	C1	HANS BUNDGAARD, Drugs of the Future, Vol. 16(5), pp. 443-458 (1991)	
	C2	BARKER, Reviews in the Neurosciences, Vol. 7, No. 3, pp. 187-214 (1996)	
	C3	LONGMORE ET AL., Can. J. Physiol. Pharmacol., Vol. 75, pp. 612-621 (1997)	
	C4	MARK S. KRAMER ET AL., Science, Vol. 281, pp. 1640-1645	
	C5	MAGGI ET AL., J. Auton. Pharmacol, Vol. 13, pp. 23-93 (1993)	
	C6	NAVARI ET AL., The New England Journal of Medicine, Vol.340, No. 3, pp. 190-195 (1999)	
	C7	MAGGI ET AL., Neuropeptides, Vol. 32(1), pp. 1-49 (1998)	
	C8	DOI ETAL., European Journal of Pharmacology, Vol. 383(3), pp. 297-303 (1999)	
	C9	YOSHINORI IKEURA ET AL., Chem. Pharm. Bull., Vol. 45(10), pp. 1642-1652 (1997)	
	-		
	-		
<del></del>			
Examiner Signature		DATE CONSIDERED	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*Unique citation designation number. Applicant is to place a check mark here if English language Translation or abstract is attached.

134855